Anzeige
Mehr »
Mittwoch, 25.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A140ML | ISIN: JE00BYSS4X48 | Ticker-Symbol: 038
Tradegate
25.06.25 | 17:57
14,630 Euro
0,00 % 0,000
1-Jahres-Chart
NOVOCURE LIMITED Chart 1 Jahr
5-Tage-Chart
NOVOCURE LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
14,65514,73018:03
14,65514,73018:03

Aktuelle News zur NOVOCURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.06.NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial5
02.06.Novocure study shows improved pancreatic cancer survival9
02.06.NovoCure's Tumor Treating Fields Boosts One-Year And Pain-Free Survival In Pancreatic Cancer Trial3
02.06.H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data4
02.06.NovoCure Ltd - 8-K, Current Report1
01.06.Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)'s TTFields Therapy Succeeds in Phase 3 Trial5
31.05.Zai Lab Limited: Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting794TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for...
► Artikel lesen
NOVOCURE Aktie jetzt für 0€ handeln
31.05.Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting428TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients...
► Artikel lesen
27.05.Novocure Announces Upcoming Investor Events243Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May...
► Artikel lesen
25.04.Why NovoCure Stock Skyrocketed This Week8
25.04.H.C. Wainwright maintains Buy on NovoCure, $38 price target9
25.04.Why NovoCure Stock Leaped 4% Higher Today4
24.04.NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 20253
24.04.Novocure outlines expansion plans for lung cancer treatment and regulatory milestones in 20253
24.04.Novocure Reports First Quarter 2025 Financial Results331Quarterly net revenues of $155 million, up 12% year-over-year, with 4,268 active patients on therapy as of March 31, 2025 Results from Phase 3 PANOVA-3 trial in pancreatic cancer accepted as...
► Artikel lesen
24.04.NovoCure GAAP EPS of -$0.31 beats by $0.15, revenue of $155M beats by $8M4
24.04.NovoCure Ltd - 10-Q, Quarterly Report2
23.04.NovoCure's Earnings: A Preview2
23.04.NovoCure Q1 2025 Earnings Preview10
23.04.Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting264Novocure (NASDAQ: NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer at the 2025 American...
► Artikel lesen
Weiter >>
63 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1